|本期目录/Table of Contents|

[1]罗皓,徐磊,赵青,等.重组人血管内皮抑素联合NX方案治疗蒽环及紫杉类药物失败的HER-2阴性晚期乳腺癌疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2018,20(06):601-605.[doi:10.3969/j.issn.1672-271X.2018.06.009]
　LUO Hao,XU Lei,ZHAO Qing,et al.Clinical observation of recombinant human endostatin combined with vinorelbine and capecitabine as third-line treatment of HER-2 negative advanced breast cancer resistant to anthracyclines and taxanes[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(06):601-605.[doi:10.3969/j.issn.1672-271X.2018.06.009]
点击复制

重组人血管内皮抑素联合NX方案治疗蒽环及紫杉类药物失败的HER-2阴性晚期乳腺癌疗效观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第20卷
期数:
2018年06期
页码:
601-605
栏目:
临床研究
出版日期:
2018-11-20

文章信息/Info

Title:
Clinical observation of recombinant human endostatin combined with vinorelbine and capecitabine as third-line treatment of HER-2 negative advanced breast cancer resistant to anthracyclines and taxanes
作者:
罗皓; 徐磊; 赵青; 任凌燕; 赵怡; 桂伟伟
作者单位：210002南京，解放军第四五四医院肿瘤科（罗皓、徐磊、赵青、任凌燕、赵怡、桂伟伟）
Author(s):
LUO Hao;  XU Lei;  ZHAO Qing;  REN Ling-yan;  ZHAO Yi;  GUI Wei-wei
（Department of Oncology，the 454th Hospital of PLA,Nanjing 210002, Jiangsu,China）
关键词:
重组人血管内皮抑素; 恩度; 长春瑞滨; 卡培他滨; 晚期乳腺癌; 抗肿瘤血管形成
Keywords:
recombinant human endostatin; endostar; vinorelbine; capecitabine; advanced breast cancer; antiangiogenesis
分类号:
R737.9
DOI:
10.3969/j.issn.1672-271X.2018.06.009
文献标志码:
A
摘要:
目的 探讨重组人血管内皮抑素联合NX方案（卡培他滨+长春瑞滨）作为三线治疗蒽环类及紫杉类药物治疗失败的HER-2阴性晚期乳腺癌的疗效及不良反应。方法 回顾性分析45例经病理证实为HER-2阴性且经蒽环类及紫杉类药物治疗失败的乳腺癌患者临床资料，其中23例采用NX化疗方案（化疗组），22例采用重组人血管内皮抑素注射液（恩度）联合NX化疗方案（联合组）。恩度30 mg加入10 mL等渗盐水24 h静脉泵入d1-7，21 d为一周期；NX方案（长春瑞滨25 mg/m2 d1、8滴注；卡培他滨1000 mg/m2早晚各服用1次，d1-14）化疗，21 d为一周期，治疗前后进行血管内皮生长因子(VEGF)定量测定，按照RECTIST1.1评估疗效；NCI-CTC3.0评价毒性反应；根据不良反应情况调整用药剂量，每2周期评估疗效。结果 联合组第2周期评估客观缓解率（RR）为45.5%,疾病控制率（DCR）为72.7%；对比化疗组RR为30.4%，DCR为65.2%，差异均无统计学意义（P>0.05）。联合组第4周期评估RR为59.1%，DCR为81.8%；对比化疗组RR为26.1%，DCR为47.8%，差异均有统计学意义（P＜0.05）。治疗后2组间VEGF值差异有统计学意义（P＜0.05），根据疗效分为有效组19例和无效组26例，有效组VEGF表达较无效组明显降低（P＜0.05）。2组间的第2周期和第4周期不良反应差异均无统计学意义（P>0.05）。结论 重组人血管内皮抑素联合NX方案作为三线方案在蒽环类及紫杉类药物失败的HER-2阴性晚期乳腺癌患者中疗效确切，较NX方案化疗具有优势。
Abstract:
Objective To analyze the efficacy and toxicities of endostar combined with vinorelbine and capecitabine as the third-line treatment of HER-2 negative patients with advanced breast cancer resistant to anthracyclines and taxanes.Methods Forty-five patients were divided into two groups. Twenty-three patients of chemotherapy group were treated with vinorelbine and capecitabine. The other 22 patients of combined group were treated with endostar combined with vinorelbine and capecitabine. Edostar (30 mg in 10 mL saline) was 24 hour continued vein pumping within the first 7 days. Vinorelbine (25 mg/m2) was injected intravenously on the first and eighth days. Capecitabine (1000 mg/m2) was taken orally twice every day within the first 14 days. One treatment cycle was 21 days. VEGF expression was measured before and after the treatment. The curative effect and toxic reaction were evaluated by RECIST1.1 and NCI.CTC3.0, respectively. The dosage was adjusted according to the adverse reaction, and the effectiveness was evaluated every two cycles.Results After two cycles of treatment, the RR and DCR of the chemotherapy group were 30.4% and 65.2%.The RR and DCR of the 22 patients of combined group were 45.5% and 72.7%, which was shown nonsignificant differences (P>0.05). After four cycles of treatment, the RR and DCR of the chemotherapy group were 26.1% and 47.8%. The RR and DCR of the 22 patients of combined group were 59.1% and 81.8%, showing significant difference (P<0.05). The VEGF expression was shown significant differences in both groups (P<0.05). According to the curative effect, these patients were divided into two groups, effective group (19 cases) and ineffective (26 cases).VEGF expression in effective group was significantly lower than that in effective group. The toxic reaction in the second and fourth cycle showed nonsignificant differences (P>0.05).Conclusion Endostar combined with vinorelbine and capecitabine as the third-line treatment showed obvious curative effect in HER-2 negative patients with advanced breast cancer resistant to anthracyclines and taxanes, thereby being superior to NX regimen.

参考文献/References:

[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[2]Petrelli F, Di Cosimo S, Lonati V,et al. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies[J]. Clin Breast Cancer,2016,16(5):327-334.
[3]Zhang J, Gu SY, Gan Y, et al. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?[J] Cancer Chemother Pharmacol,2013,71(1):103-113.
[4]Danza K, Pilato B, Lacalamita R, et al. Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer[J]. Eur J Hum Genet,2013,21(8):824-830.
[5]awicki S, Zajkowska M, Gaz·ewska EK, et al. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer[J]. Onco Targets Ther,2016,9(Issue 1):911-919.
[6]王金万，孙燕，刘永煜，等. 重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J]. 中国肺癌杂志,2005,8(4):283-290.
[7]吴建华，梁国华，凌志琴，等. 恩度联合化疗治疗多种晚期恶性肿瘤的临床观察[J]. 吉林医学,2014,35(32):7116-7117.
[8]周幸，施鑫，吴苏稼，等. 重组人血管内皮抑制素(恩度)联合化疗治疗骨肉瘤的临床研究[J]. 医学研究生学报，2012，25(1):39-42.
[9]Langkjer ST, Ejlertsen B, Mouridsen H, et al. Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group[J]. Acta oncologica (Stockholm, Sweden)，2008，47(4):735.
[10]Mansour M, Mourad C. Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer[J]. Cancer Chemother Pharmacol，2013，72(2):429-435.
[11]Cybulska-Stopa B, Ziobro M, Skoczek M, et al. Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer[J]. Contemp Oncol，2013，17(1):78-82.
[12]Kotsori AA, Dolly S, Sheri A, et al. Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer? [J]Oncology，2010，79(5-6):331.
[13]王楠，代醒，王留兴. 长春瑞滨联合希罗达对蒽环类/紫杉类治疗后复发转移性乳腺癌的疗效观察[J]. 肿瘤防治研究，2013，40(7):698-701.
[14]Folkman J. Role of angiogenesis in tumor growth and metastasis[J]. Semin Cancer Biol，2002，29(3):65-71.
[15]伍钢, 李振宇, 朱芳, 等. 恩度诱导抑制性VEGFA选择性剪切异构体VEGF165b的表达及其意义[J]. 中华肿瘤防治杂志，2010，17(1):37-40.
[16]耿海云，陈映霞，秦叔逵，等. 重组人血管内皮抑素联合紫杉醇对高侵袭性胃癌细胞增殖和侵袭作用的影响[J]. 医学研究生学报，2014，27(6):587-591.
[17]谭叶，王效军，李美玲，等. 重组人内皮抑素联合放疗对小鼠胃癌移植瘤的生长抑制作用及机制的研究[J]. 中华放射医学与防护杂志, 2017,37(3):187-192.
[18]Li Y, Wei X, Zhang S, Zhang J. Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging[J]. Tumor Biology，2015，36(11):8755-8760.
[19]孙秀华，张红梅，徐佳维，等. 重组人血管内皮抑素逆转人肺腺癌A549/DDP细胞耐药性研究[J]. 国际肿瘤学杂志，2010，37(7):550-554.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2018-11-20